108 related articles for article (PubMed ID: 17006831)
21. Serum cytokeratins determination in differentiated thyroid carcinoma.
Appetecchia M; Meçule A; Ducci M; Palma L; Castelli M
J Exp Clin Cancer Res; 2001 Jun; 20(2):253-6. PubMed ID: 11484983
[TBL] [Abstract][Full Text] [Related]
22. bcl2, p53 and bax in thyroid tumors and their relation to apoptosis.
Farid P; Gomb SZ; Péter I; Szende B
Neoplasma; 2001; 48(4):299-301. PubMed ID: 11712682
[TBL] [Abstract][Full Text] [Related]
23. Serum soluble Fas ligand (sFasL) in patients with primary squamous cell carcinoma of the esophagus.
Kozlowski M; Kowalczuk O; Sulewska A; Dziegielewski P; Lapuc G; Laudanski W; Niklinska W; Chyczewski L; Niklinski J; Laudanski J
Folia Histochem Cytobiol; 2007; 45(3):199-204. PubMed ID: 17951168
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis of metastatic tumours to the thyroid gland by fine needle aspiration biopsy.
Buła G; Waler J; Niemiec A; Koziołek H; Bichalski W; Gawrychowski J
Endokrynol Pol; 2010; 61(5):427-9. PubMed ID: 21049452
[TBL] [Abstract][Full Text] [Related]
25. Molecular markers for discrimination of benign and malignant follicular thyroid tumors.
Fryknäs M; Wickenberg-Bolin U; Göransson H; Gustafsson MG; Foukakis T; Lee JJ; Landegren U; Höög A; Larsson C; Grimelius L; Wallin G; Pettersson U; Isaksson A
Tumour Biol; 2006; 27(4):211-20. PubMed ID: 16675914
[TBL] [Abstract][Full Text] [Related]
26. Role of p53, CD44V6 and CD57 in differentiating between benign and malignant follicular neoplasms of the thyroid.
Nasir A; Catalano E; Calafati S; Cantor A; Kaiser HE; Coppola D
In Vivo; 2004; 18(2):189-95. PubMed ID: 15113046
[TBL] [Abstract][Full Text] [Related]
27. Significance of serum soluble Fas ligand in patients with bladder carcinoma.
Mizutani Y; Hongo F; Sato N; Ogawa O; Yoshida O; Miki T
Cancer; 2001 Jul; 92(2):287-93. PubMed ID: 11466681
[TBL] [Abstract][Full Text] [Related]
28. Carcinoembryonic antigen mRNA in blood: distinguishing follicular thyroid carcinoma from adenoma.
Sato T; Nakano S; Yamashita J
Thyroid; 2003 Sep; 13(9):891-2. PubMed ID: 14588107
[No Abstract] [Full Text] [Related]
29. Prognostic Value of Soluble Death Receptor Ligands in Patients with Transitional Cell Carcinoma of Bladder.
Ben Bahria-Sediki I; Chebil M; Sampaio C; Martel-Frachet V; Cherif M; Zermani R; Rammeh S; Ben Ammar Gaaied A; Bettaieb A
Urol Int; 2018; 100(4):476-484. PubMed ID: 29719304
[TBL] [Abstract][Full Text] [Related]
30. [Differentiated thyroid gland carcinomas in "autonomous adenomas" in childhood].
Müller A; Goretzki P; Witte J; Gerharz P; Röher HD
Chirurg; 1995 Oct; 66(10):1018-20. PubMed ID: 8529444
[TBL] [Abstract][Full Text] [Related]
31. Examination of CD26/DPPIV, p53, and PTEN expression in thyroid follicular adenoma.
Miyake Y; Aratake Y; Sakaguchi T; Kiyoya K; Kuribayashi T; Marutsuka K; Ohno E
Diagn Cytopathol; 2012 Dec; 40(12):1047-53. PubMed ID: 22086610
[TBL] [Abstract][Full Text] [Related]
32. Thyroid follicular carcinoma: sonographic features of 50 cases.
Sillery JC; Reading CC; Charboneau JW; Henrichsen TL; Hay ID; Mandrekar JN
AJR Am J Roentgenol; 2010 Jan; 194(1):44-54. PubMed ID: 20028904
[TBL] [Abstract][Full Text] [Related]
33. Follicular lesions of the thyroid: a surgical perspective.
Williams MJ; Spence RA; Lioe TF
Ulster Med J; 2015 Jan; 84(1):48. PubMed ID: 25964705
[No Abstract] [Full Text] [Related]
34. Serum Immunoproteomics Combined With Pathological Reassessment of Surgical Specimens Identifies TCP-1ζ Autoantibody as a Potential Biomarker in Thyroid Neoplasia.
Belousov PV; Bogolyubova AV; Kim YS; Abrosimov AY; Kopylov AT; Tvardovskiy AA; Lanshchakov KV; Sazykin AY; Dvinskikh NY; Bobrovskaya YI; Selivanova LS; Shilov ES; Schwartz AM; Shebzukhov YV; Severskaia NV; Vanushko VE; Moshkovskii SA; Nedospasov SA; Kuprash DV
J Clin Endocrinol Metab; 2015 Sep; 100(9):E1206-15. PubMed ID: 26196948
[TBL] [Abstract][Full Text] [Related]
35. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
36. Serum ferritin in thyroid cancer.
Deshpande UR; Nadkarni GD; Samuel AM
Thyroid; 1993; 3(4):301-3. PubMed ID: 8118224
[TBL] [Abstract][Full Text] [Related]
37. [Follicular thyroid tumor as a diagnostic and therapeutic problem].
Król R; Heitzman M; Pawlicki J; Ziaja J; Cierpka L
Postepy Hig Med Dosw (Online); 2004; 58():490-4. PubMed ID: 15765010
[TBL] [Abstract][Full Text] [Related]
38. Clinical utility of serum Interleukin-1 receptor antagonist levels as a diagnostic and prognostic assay in surgical patients.
Kapoor S
Langenbecks Arch Surg; 2009 Mar; 394(2):401-2; author reply 403. PubMed ID: 18825404
[No Abstract] [Full Text] [Related]
39. Clinicopathologic significance of histologic vascular invasion in papillary and follicular thyroid carcinomas.
Furlan JC; Bedard YC; Rosen IB
J Am Coll Surg; 2004 Mar; 198(3):341-8. PubMed ID: 14992733
[TBL] [Abstract][Full Text] [Related]
40. Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications.
Chevillard S; Ugolin N; Vielh P; Ory K; Levalois C; Elliott D; Clayman GL; El-Naggar AK
Clin Cancer Res; 2004 Oct; 10(19):6586-97. PubMed ID: 15475448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
